Pacira

PCRX Investors Invited to Head Class Action Lawsuit Against Pacira BioSciences Over Alleged Securities Fraud

by

Investors in Pacira BioSciences, Inc., a New Jersey-based pharmaceutical company, have been granted the opportunity to lead a securities class action lawsuit over allegations of fraudulent activity. The lawsuit surrounds claims that Pacira misrepresented its financial status and the efficacy of certain products, thereby inflating its stocks artificially. The legal challenge roots from assertions that Pacira failed to disclose operational and business setbacks, particularly concerning the effectiveness and market acceptance of EXPAREL, a non-opioid pain management drug that is one of the company’s top products. Allegedly, the company made misleading statements or failed to provide … Read more

Investors Alert: Join Pacira BioSciences Class Action Lawsuit by March 14, 2025 – Legal Representation Available Through The Gross Law Firm for PCRX Shareholders

by

Investors in Pacira BioSciences, Inc. are facing critical financial concerns following allegations of securities fraud, prompting a class action lawsuit that demands immediate attention. With a deadline of March 14, 2025, for Pacira’s shareholders to contact The Gross Law Firm to discuss their legal options, time is of the essence for those impacted by the company’s recent stock performance issues. Pacira BioSciences, known for its non-opioid pain management drugs, has come under legal scrutiny after accusations surfaced that the company may have misled investors about its business and financial prospects. These allegations suggest that Pacira … Read more

PCRX Shareholders Invited to Spearhead Class Action Lawsuit Against Pacira BioSciences for Alleged Securities Fraud

by

Investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) are presented with a significant opportunity as the deadline approaches to apply as lead plaintiff in a securities fraud lawsuit. The case under consideration alleges misleading statements by the company, potentially impacting shareholder investments. Investors who have suffered losses connected to Pacira’s actions, particularly during the period between April 23, 2021, and August 9, 2022, are urged to step forward. The lawsuit, managed by The Schall Law Firm, a Los Angeles-based firm with expertise in securities class action and shareholder rights litigation, focuses on how the company might … Read more